Bispecific antibody treatment of multiple myeloma: latest updates from the 2022 ASH annual meeting
Background: Effective novel therapies for multiple myeloma (MM) patients who are unresponsive to conventional treatments (triple-class refractory) are an urgent need. Bispecific antibodies (BsAbs) offer a promising new approach to stimulate T cells and induce tumor cell death by targeting molecules...
Salvato in:
| Autori principali: | , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
SAGE Publishing
2023-11-01
|
| Serie: | Therapeutic Advances in Chronic Disease |
| Accesso online: | https://doi.org/10.1177/20406223231213251 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|